HKMPY OTC
Hikma Pharmaceuticals PLC
1W: +0.5%
1M: +5.7%
3M: +0.5%
YTD: +6.3%
1Y: -5.2%
3Y: -9.6%
5Y: -22.4%
$44.35
+0.00 (+0.00%)
Credit Risk of going bust: lower than 53% of companies Debt: 29.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.43 (down 97%), Hikma Pharmaceuticals PLC would be worth roughly what it owes.
Total debt $1.96B against a stock market value of $4.64B.
Distance to default 5.38 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.04B (short-term plus half of long-term), stock volatility 38.0%; Altman Z'' 4.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $1.96B against a stock market value of $4.64B.
Distance to default 5.38 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.04B (short-term plus half of long-term), stock volatility 38.0%; Altman Z'' 4.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$3.4B
+7.3% ▲
5Y CAGR: +7.5%
Gross Profit
$1.3B
-5.0% ▼
5Y CAGR: +2.3%
Operating Income
$625M
+2.2% ▲
5Y CAGR: +1.6%
Net Income
$403M
+12.2% ▲
5Y CAGR: -1.3%
EPS (Diluted)
$3.62
+12.4% ▲
5Y CAGR: +0.0%
EBITDA
$838M
+15.3% ▲
5Y CAGR: +2.3%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.6B | $2.5B | $2.9B | $3.1B | $3.4B |
| YoY Growth | +9.1% | -1.4% | +14.2% | +8.8% | +7.3% |
| Cost of Revenue | $1.3B | $1.3B | $1.5B | $1.7B | $2.0B |
| Gross Profit | $1.3B | $1.2B | $1.4B | $1.4B | $1.3B |
| Gross Margin | 51.0% | 49.2% | 48.9% | 45.3% | 40.0% |
| R&D Expenses | $143M | $144M | $149M | $141M | $151M |
| SG&A Expenses | $488M | $509M | $638M | $568M | $567M |
| Operating Expenses | $719M | $956M | $1.0B | $803M | $719M |
| Operating Income | $582M | $282M | $367M | $612M | $625M |
| Operating Margin | 22.8% | 11.2% | 12.8% | 19.6% | 18.6% |
| Interest Expense | $69M | $70M | $87M | $88M | $106M |
| Income Before Tax | $543M | $233M | $281M | $454M | $520M |
| Tax Expense | $124M | $42M | $89M | $93M | $112M |
| Net Income | $421M | $188M | $190M | $359M | $403M |
| Net Margin | 16.5% | 7.5% | 6.6% | 11.5% | 12.0% |
| EPS (Diluted) | $3.62 | $1.68 | $1.72 | $3.22 | $3.62 |
| EBITDA | $766M | $688M | $559M | $727M | $838M |
| Shares Outstanding | 116M | 112M | 111M | 112M | 111M |